Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer
Christopher Poole(Guy's Hospital), Christopher Twelves(Bradford Royal Infirmary), Karen McAdam(Peterborough City Hospital), Janet Dunn(National Health Service), Daniel Rea(University Hospitals Birmingham NHS Foundation Trust), Adrian Murray Brunt(Western Infirmary), D. Spooner(Queen Elizabeth Hospital Birmingham), Peter Simmonds(University of Turku), R. K. Agrawal(Royal Shrewsbury Hospital), Helena Earl(University of Cambridge), Louise Hiller(University of Warwick), S.M. O'Reilly(Charing Cross Hospital), Robert Grieve, S. M. Crawford(The University of Texas of the Permian Basin), Robert Leonard(National Cancer Centre Japan), Andrew Stanley(Birmingham City Hospital), Indrajit Fernando(NIHR Surgical Reconstruction and Microbiology Research Centre), Peter Harvey(St James's University Hospital), Janine Mansi(Guy's and St Thomas' NHS Foundation Trust), Sarah Bathers(Cancer Research UK Clinical Trials Unit)
Cited by 189
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Consensus Proposals for a Unified System of Nomenclature of Hepatitis C Virus Genotypes *
|Hepatology|2005|1.5k
Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
|Journal of General Virology|1993|1.4k